PDF
ZENODO
Published
2026-04-27
Section
Articles
How to Cite
How to Cite
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF GENETIC MARKERS OF MOTOR NEURON DISEASE.
Akbarova Saida
associate professor of Normal physiology department of Andijan state medical institute.
Keywords: motor neuron disease, amyotrophic lateral sclerosis, TARDBP, SOD1, and FUS genes, cytokine (interleukin 1, 6, tumor necrosis factor α).
Abstract
Genetic studies have significantly expanded the understanding of motor neuron disease and related motor neuron damage. Currently, the TARDBP, SOD1, and FUS genes are listed as the main genetic determinants most associated with the disease, and some sources include mutations in the IL-6 and TBK1 genes involved in the regulation of inflammatory processes among the important genes that cause severe neurodegenerative changes. The existence of interpopulation differences indicates the need to study genetic factors separately in different regions.
References
1. Agah E., Saleh F., Sanjari Moghaddam H., et al. CSF and blood biomarkers in amyotrophic lateral sclerosis: protocol for a systematic review and meta-analysis // Syst. Rev. – 2018; 7: 237.
2. Al-Chalabi, A. Amyotrophic lateral sclerosis: moving towards a new classification system / A. Al-Chalabi, O. Hardiman, M.C. Kiernan // Lancet Neurol. – 2016. – Vol. 15. – № 11. – rr. 1182–1194.
3. Andrew A.S., Pioro E.P., Li M., et al. The incidence of amyotrophic lateral sclerosis in Ohio 2016–2018: the Ohio population-based ALS registry // Neuroepidemiology. – 2021; 55(3): 196–205.
4. Antao V.C., Horton D.K. The National Amyotrophic Lateral Sclerosis (ALS) Registry // Journal Environ Health. – 2012; 75: 28–30.
5. Bä umer D., Talbot K., Turner M.R. Advances in motor neurone disease // J R Soc Med. – 2014 Jan; 107(1): 14-21. DOI:10.1177/0141076813511451.
6. Bedlack R.S., Vaughan T., Wicks P., Heywood J., et al. How common are ALS plateaus and reversals? // Neurology. – 2016; 86: 808–812.
7. Bhandari R., Kuhad A., Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis // Drugs Today (Barc). – 2018; 54: 349–60.
8. Bledsoe M.J., Rechtman L., Wagner L., Mehta, et al. Analysis of biospecimen demand and utilization of samples from the National Amyotrophic Lateral Sclerosis Biorepository // Biopreserv Biobanking. – 2021; 19(5): 432–437.
9. Boostani R., Olfati N., Shamshiri H., et al. Iranian clinical practice guideline for amyotrophic lateral sclerosis // Front Neurol. – 2023 Jun 2; 14: 1154579.
10. Brenner D., Weishaupt J.H. Update on amyotrophic lateral sclerosis genetics // Curr. Opin. Neurol. – 2019; 32 (5): 735–739.
11. Brotman R.G., Moreno-Escobar M.C., Joseph J., et al. Amyotrophic Lateral Sclerosis // American Journal of Medicine, 2023.
12. Brown R.H.; Al-Chalabi A. Amyotrophic lateral sclerosis // N. Engl. J. Med. – 2017; 377: 162–172. [CrossRef] [PubMed].
13. Bryan L., Kaye W., Antao V., et al. Preliminary results of National Amyotrophic Lateral Sclerosis (ALS) registry risk factor survey data // PLoS ONE. – 2016; 11(4): e0153683.
14. Burkhardt C., Neuwirth C., Sommacal A., Andersen P.M., Weber M. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS) A post-mortem study of 80 ALS patients // PLoS ONE. – 2017; 12: e0177555 [CrossRef].
15. Chew S., Atassi N. Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis // Front Neurol. – 2019; 10: 135.
16. Chiò A., Logroscino G., Traynor B., Collins J., Simeone J., Goldstein L., White L. Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature // Neuroepidemiology. – 2013; 41: 118–130. [CrossRef].
17. De Carvalho M., Kiernan M.C., Swash M. Fasciculation in amyotrophic lateral sclerosis: origin and path-ophysiological relevance // Journal Neurol Neurosurg Psychiatry. – 2017; 88 (9): 773–779.
18. De Marchi F., Munitic I., Amedei A., et al. Interplay between immunity and amyotrophic lateral sclerosis: clinical impact // Neurosci Biobehav Rev. – 2021; 127: 958–978.831
19. Doi Y., Atsuta N., Sobue G., Morita M., Nakano I. Prevalence and incidence of amyotrophic lateral sclerosis in Japan // J. Epidemiol. – 2014; 24: 494–499. [CrossRef].
20. Eisen A., Braak H., Del Tredici K., Lemon R., Ludolph A.C., Kiernan M.C. Cortical influences drive amyotrophic lateral sclerosis // J. Neurol. Neurosurg. Psychiatry. – 2017; 88: 917–924. [CrossRef].
21. Fujimori K., Ishikawa M., Otomo A., et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent // Nat Med. – 2018.
22. Gebere-Michael S., Johnston J., Metaferia G., et al. Bilaterally symmetric cervical spondylotic amyotrophy: A novel presentation and review of the literature // Journal Neurol Sci. – 2010. – Vol. 290. – № 1–2. – pp. 142–145.
